¾Ë·¯ºñµåÁ¡¾È¾× 6mL ALLERVID EYE DROPS 1ml
Àü¹®ÀǾàǰ | ±Þ¿©
|
¾Ë¸²:
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù.
Àü¹®/ÀϹÝ
Àü¹®
´Ùȸ¿ë: ºÒÅõ¸íÇÑ Èò»ö ¿ë±â¿¡ µç ¹«»ö-¹ÌȲ»öÀÇ Á¡¾ÈÁ¦
ÀÏȸ¿ë: ¹«»ö-¹ÌȲ»öÀÇ Åõ¸íÇÑ ¾×ÀÌ ¹«»öÅõ¸íÇÑ ÇÃ¶ó½ºÆ½ ¿ë±â¿¡ µç Á¡¾ÈÁ¦
Á¦Á¶È¸»ç
(ÁÖ)¿ÉÅõ½ºÁ¦¾à
ÆÇ¸Åȸ»ç
(ÁÖ)¿ÉÅõ½ºÁ¦¾à
Çã°¡Á¤º¸
Á¤»ó
(2010.12.27)
BIT ¾àÈ¿ºÐ·ù
¾È°ú¿ë Ç׾˷¯ÁöÁ¦(Eye steroids & antiallergics)
º¹ÁöºÎºÐ·ù
131[¾È°ú¿ëÁ¦ ]
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå
674100603Àú°¡¾à ´ëü Àμ¾Æ¼ºê Áö±Þ ´ë»ó \6,282 ¿ø/6mL/º´(2023.07.01) (ÇöÀç¾à°¡) \6,282 ¿ø/6mL/º´(2017.02.01) (º¯°æÀü¾à°¡)
ATCÄÚµå
Olopatadine / S01GX09
NDCÄÚµå
[Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]
[Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]
[NDC Number Search _ NDCÄÚµå·Î °Ë»ö]
¼ººÐ / ÇÔ·®
[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]
÷°¡Á¦
¸ê±ÕÁ¤Á¦¼ö ,
º¥ÀßÄÚ´½¿°È¹° ,
¼ö»êȳªÆ®·ý ,
¿°»ê ,
¿°È³ªÆ®·ý ,
Àλê¼ö¼Ò³ªÆ®·ý¼öȹ° ,
ÀλêÀ̼ö¼Ò³ªÆ®·ý ,
ÁÖ»ç¿ë¼ö
À¯·áȸ¿ø °áÀç½Ã ¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸ ¸¦
ÀÌ¿ë ÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·Ï Àº Àü¹®È¸¿ø À¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
Çã°¡Á¤º¸
Ç׸ñ
³»¿ë
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇѱݾ×
674100603
Àú°¡¾à ´ëü Àμ¾Æ¼ºê Áö±Þ ´ë»ó
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\6,282 ¿ø/6mL/º´(2023.07.01) (ÇöÀç¾à°¡)
\6,282 ¿ø/6mL/º´(2017.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
ºü¸¥Á¶È¸
Á¦Ç°¼º»ó
´Ùȸ¿ë: ºÒÅõ¸íÇÑ Èò»ö ¿ë±â¿¡ µç ¹«»ö-¹ÌȲ»öÀÇ Á¡¾ÈÁ¦
ÀÏȸ¿ë: ¹«»ö-¹ÌȲ»öÀÇ Åõ¸íÇÑ ¾×ÀÌ ¹«»öÅõ¸íÇÑ ÇÃ¶ó½ºÆ½ ¿ë±â¿¡ µç Á¡¾ÈÁ¦
[Á¦ÇüÁ¤º¸ È®ÀÎ]
Æ÷À塤À¯Åë´ÜÀ§
6ml
Æ÷À塤ÄÚµå´ÜÀ§
¾àǰ±Ô°Ý
´ÜÀ§
Æ÷ÀåÇüÅÂ
´ëÇ¥ÄÚµå
Ç¥ÁØÄÚµå
ºñ°í
6¹Ð¸®¸®ÅÍ
1 °³
º´
8806741006002
8806741006033
ÁÖ¼ººÐÄÚµå
391737COS
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
Çã°¡»çÇ× ¿ø¹®Á¶È¸
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
È¿´ÉÈ¿°ú
[ÀûÀÀÁõ º° °Ë»ö]
¾Ë·¹¸£±â¼º °á¸·¿°À¸·Î ÀÎÇÑ Áõ»ó Ä¡·á
¿ë¹ý¿ë·®
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
1ȸ 1¹æ¿ï 1ÀÏ 2ȸ(6~8½Ã°£ °£°Ý) Á¡¾ÈÇÑ´Ù.
ÇÊ¿äÇÑ °æ¿ì ÃÖ´ë 4°³¿ù µ¿¾È Ä¡·áÇÒ ¼ö ÀÖ´Ù.
Á¡¾È ÈÄ ³²Àº ¾×°ú ¿ë±â´Â ¹Ù·Î ¹ö¸°´Ù.(ÀÏȸ¿ë¿¡ ÇÑÇÔ)
±Ý±â
ÀÌ ¾àÀÇ ÁÖ¼ººÐ ¶Ç´Â ÀÌ ¾àÀÇ ±¸¼º¼ººÐ¿¡ °ú¹ÎÁõ ȯÀÚ
ÀÌ»ó¹ÝÀÀ
1) ÀÌ ¾à 1 mg/ml ¹× 2 mg/ml Á¡¾È¾×ÀÇ ÀÓ»ó½ÃÇè¿¡¼ ´ÙÀ½°ú °°Àº ÀÌ»ó¹ÝÀÀÀÌ º¸°íµÇ¾úÀ¸¸ç, ´ÙÀ½ÀÇ ±âÁØ¿¡ µû¶ó ºÐ·ùµÇ¾ú´Ù: ¸Å¿ì ÈçÇÏ°Ô (¡Ã 1/10), ÈçÇÏ°Ô (¡Ã 1/100¿¡¼ <1/10), ÈçÇÏÁö ¾Ê°Ô (¡Ã1/1,000¿¡¼ <1/100), µå¹°°Ô (¡Ã1/10,000¿¡¼ <1/1,000) ¹× ¸Å¿ì µå¹°°Ô (<1/10,000). °¢°¢ÀÇ ºóµµ ±×·ì ³»¿¡¼, ÀÌ»ó¾à¹°¹ÝÀÀÀº ÁßÁõµµ°¡ °¨¼ÒÇÏ´Â ¼øÀ¸·Î ³ªÅ¸³½´Ù.
±â°ü
ÀÌ»ó¹ÝÀÀ
½Å°æ°è
ÈçÇÏÁö ¾Ê°Ô: µÎÅë, ¹Ì°¢ÀÌ»ó
µå¹°°Ô: ¾îÁö·¯¿ò
¾È°ú°è
ÈçÇÏÁö ¾Ê°Ô: Á¡¸ð¾ç °¢¸·¿°, °¢¸·¿°, ¾È±¸ ÅëÁõ, ¾È±¸ °ÇÁ¶, ¾È°Ë ºÎÁ¾, ´«°¡·Á¿ò, ´« ºÐºñ¹°, ¾È±¸ ÃæÇ÷, ¾È°Ë¿¬ÀÇ °¢ÁúÈ, ¾È±¸ ºÒÆí°¨
µå¹°°Ô: ´«ºÎ½É, ½Ã¾ßÈ帲, ¾È°Ë È«¹Ý
È£Èí±â°è
ÈçÇÏÁö ¾Ê°Ô: ÄÚ °ÇÁ¶
µå¹°°Ô: ºñ¿°
¼Òȱâ°è
µå¹°°Ô: ±¸° °ÇÁ¶
ÇǺΠ¹× ÇÇÇÏÁ¶Á÷°è
µå¹°°Ô: Á¢Ã˼º ÇǺο°
Àü½Å ¹× Åõ¿© ºÎÀ§ ÀÌ»ó
ÈçÇÏÁö ¾Ê°Ô: ÇÇ·Î
2) ±× ¿Ü ÀÌ ¾à 1mg/mL Á¡¾È¾×ÀÇ ÀÓ»ó½ÃÇè¿¡¼ Ãß°¡·Î º¸°íµÈ ÀÌ»ó¹ÝÀÀÀº ´ÙÀ½°ú °°´Ù.
(1) ¾È±¸¿Í °ü·ÃµÈ Áõ»óÀ¸·Î ´«ÀÇ °úµµÇÑ ¹Î°¨¼º Áõ°¡ µîÀÌ ¶§¶§·Î ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
(2) ¾È±¸ ¿Ü Áõ»óÀ¸·Î ¹«·Â°¨, °¨±â, °ú¹ÎÁõ, ±¸¿ª, Àεο°, ºÎºñµ¿¿°, È«¹Ý, º¹Åë, °£±â´ÉÀå¾Ö, Ȳ´Þ, Ç÷¾Ð»ó½Â, ¹éÇ÷±¸, ¸²ÇÁ±¸ÀÇ °¨¼Ò, Ç÷Áß Å©·¹¾ÆÆ¼´Ñ¡¤BUNÀÇ »ó½Â, ¹è´¢ °ï¶õÀÌ ¶§¶§·Î º¸°íµÇ¾ú´Ù.
3) ÇØ¿Ü ½ÃÆÇ ÈÄ Á¶»ç¿¡¼ È®ÀÎµÈ Ãß°¡ÀûÀÎ ÀÌ»ó¾à¹°¹ÝÀÀ¿¡´Â ´ÙÀ½ÀÌ Æ÷ÇԵȴÙ. ÀÔ¼öµÈ ÀÚ·á·ÎºÎÅÍ ºóµµ¸¦ ÃßÁ¤ÇÒ ¼ö ¾ø´Ù.
(1) ¾È°úÀå¾Ö : ´«¹°ºÐºñÁõ°¡
4) ±¹³» ½ÃÆÇÈÄ Á¶»ç°á°ú
±¹³»¿¡¼ Àç½É»ç¸¦ À§ÇÏ¿© 6³â µ¿¾È 848¸íÀÇ È¯ÀÚ¸¦ ´ë»óÀ¸·Î ½Ç½ÃÇÑ ½ÃÆÇ ÈÄ Á¶»ç°á°ú ÀÌ»ó¹ÝÀÀÀÇ ¹ßÇöÁõ·ÊÀ²Àº Àΰú°ü°è¿Í »ó°ü¾øÀÌ 1.46%(12·Ê/822·Ê, ÃÑ 13°Ç)·Î ³ªÅ¸³µÀ¸¸ç, º¸°íµÈ ÀÌ»ó¹ÝÀÀÀº ¾ÈÀÚ±Ø, ¾ÈÃæÇ÷, °¢¸·¿°, ¾È±¸°ÇÁ¶, ¾ÈÅëÀ̾ú´Ù.
5) ÷°¡Á¦ : ÀÌ ¾àÀº Àλ꿰À» Æ÷ÇÔÇϰí ÀÖ´Ù.
»ó´çÇÑ °¢¸· ¼Õ»óÀÌ ÀÖ´Â ÀϺΠȯÀÚ¿¡¼ Àλ꿰 ÇÔÀ¯ Á¡¾È¾×ÀÇ »ç¿ë°ú ¿¬°üµÇ¾î °¢¸· ¼®È¸ÈÀÇ »ç·Ê°¡ ¸Å¿ì µå¹°°Ô(0.01% ¹Ì¸¸) º¸°íµÈ ¹Ù ÀÖ´Ù.
»óÈ£ÀÛ¿ë
ÀÌ ¾àÀÇ »óÈ£ÀÛ¿ë¿¡ °üÇÑ ¿¬±¸´Â ½Ç½ÃµÇÁö ¾Ê¾Ò´Ù.
Related FDA Approved Drug
Á¤º¸¿ä¾à
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
ÄÚµå ¹× ºÐ·ùÁ¤º¸
Á¦Ç°Á¤º¸
Ç׸ñ
³»¿ë
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇѱݾ×
674100603
Àú°¡¾à ´ëü Àμ¾Æ¼ºê Áö±Þ ´ë»ó
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\6,282 ¿ø/6mL/º´(2023.07.01) (Ãֽžడ)
\6,282 ¿ø/6mL/º´(2017.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
Á¦Ç°¼º»ó
´Ùȸ¿ë: ºÒÅõ¸íÇÑ Èò»ö ¿ë±â¿¡ µç ¹«»ö-¹ÌȲ»öÀÇ Á¡¾ÈÁ¦
ÀÏȸ¿ë: ¹«»ö-¹ÌȲ»öÀÇ Åõ¸íÇÑ ¾×ÀÌ ¹«»öÅõ¸íÇÑ ÇÃ¶ó½ºÆ½ ¿ë±â¿¡ µç Á¡¾ÈÁ¦
[Á¦ÇüÁ¤º¸ È®ÀÎ]
´ëü°ü·Ã
»ýµ¿¼º ½ÃÇè ¿Ï·á
Æ÷À塤À¯Åë´ÜÀ§
6ml
º¸°ü¹æ¹ý
Â÷±¤±â¹Ð¿ë±â, ½Ç¿Âº¸°ü(1~30¡É)
º¹¾àÁ¤º¸
Ç׸ñ
³»¿ë
LACTmed ¹Ù·Î°¡±â
[¹Ù·Î°¡±â]
¾à¸®ÀÛ¿ë
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
Ãà¾àº¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
º¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
ÀӺο¡´ëÇÑÅõ¿©
*
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
 
FDA : Cµî±Þ
*
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
*
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
Pharmacokinetics
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
º¹¾à¶óº§
À̹ÌÁö
º¹¾à¼³¸í
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù.
*
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù.
*
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù.
*
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù.
Á¦Çüº° º¹¾àÁöµµ
[Á¡¾È¾×]
º¸°ü»ó ÁÖÀÇ
Á¶Á¦½Ã ÁÖÀÇ
½É»çÁ¤º¸
ÇмúÁ¤º¸
Ç׸ñ
³»¿ë
DUR (ÀǾàǰ»ç¿ëÆò°¡)
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
Mechanism of Action
Olopatadine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Olopatadine is a selective histamine H1 antagonist and binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors.
Pharmacology
Olopatadine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Used to treat allergic conjunctivitis (itching eyes), olopatadine inhibits the release of histamine from mast cells. It is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells.
Absorption
Olopatadine¿¡ ´ëÇÑ Absorption Á¤º¸ Ophthalmic use of olopatadine usually does not produce measurable plasma concentrations.
Pharmacokinetics
Olopatadine HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
ÀÛ¿ë¹ßÇö½Ã°£: ¾Ë·¯Áö¼º °á¸·¿°, ±¹¼ÒÁ¡¾ÈÁ¦- 30ºÐ À̳»
ÀÛ¿ëÁö¼Ó½Ã°£: ¾Ë·¯Áö¼º °á¸·¿°, ±¹¼ÒÁ¡¾ÈÁ¦- 8½Ã°£
ÃÖ°íÈ¿°ú ¹ßÇö½Ã°£: ±¹¼ÒÁ¡¾ÈÁ¦- 2½Ã°£ À̳»
Èí¼ö:
1)±¹¼ÒÁ¡¾ÈÁ¦ – ¼Ò·® (0.15%ÀÇ olopatadine ophthalmic solutionÀ» 12½Ã°£¸¶´Ù 2ÁÖ°£ Åõ¿©½Ã Ç÷Áß ¾à¹°³óµµ´Â 0.5 ng/mL
´Ü¹é°áÇÕ: »ç¶÷¿¡°Ô¼´Â °üÂûµÇÁö ¾Ê¾ÒÀ½. (½ÇÇèÀûÀ¸·Î ·§Æ®¿¡¼´Â ¾à 44%)
´ë»ç:
1)±¹¼ÒÁ¡¾ÈÁ¦ - Mono-desmethyl metabolite(ºñȰ¼ºÇü)¿Í N-oxide derivative(ºñȰ¼ºÇü)À¸·Î ´ë»ç
¼Ò½Ç:
1)±¹¼ÒÁ¡¾ÈÁ¦ – ¹Ìº¯Èü·Î¼ ½Å¹è¼³ 60-70%ÀÓ.
2)°æ±¸Á¦ – 5mgÀ» 1ȸ °æ±¸Åõ¿©½Ã, 48½Ã°£³»¿¡ ¹Ì´ë»çü·Î 68%°¡ ´¢·Î ¹è¼³.
À¯Áó¹è¼³: ·§Æ®¿¡°Ô °æ±¸Åõ¿©½Ã À¯ÁóºÐºñ°¡ °üÂûµÊ. ±×·¯³ª ±¹¼Ò¿ëÁ¦°¡ »ç¶÷ À¯ÁóÀ¸·Î ¹è¼³µÇÁö´Â ¾Ë·ÁÁ®ÀÖÁö ¾ÊÀ½.
¹Ý°¨±â: Á¡¾ÈÁ¦-3½Ã°£, °æ±¸Á¦- ¾à 8.75½Ã°£
CYP450 Drug Interaction
[CYP450 TableÁ÷Á¢Á¶È¸]
Drug Target
[Drug Target]
Description
Olopatadine¿¡ ´ëÇÑ Description Á¤º¸ Used to treat allergic conjunctivitis (itching eyes), olopatadine inhibits the release of histamine from mast cells. It is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells.
Dosage Form
Olopatadine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Liquid Ophthalmic
Drug Category
Olopatadine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Allergic AgentsAnti-Inflammatory Agents, Non-SteroidalAntihistaminesHistamine H1 AntagonistsHistamine H1 Antagonists, Non-Sedating
Smiles String Canonical
Olopatadine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN(C)CCC=C1C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2
Smiles String Isomeric
Olopatadine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2
InChI Identifier
Olopatadine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8-/f/h23H
Chemical IUPAC Name
Olopatadine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-[(11Z)-11-(3-dimethylaminopropylidene)-6H-benzo[c][2]benzoxepin-2-yl]acetic acid
»ç¿ëÀÚÄÁÅÙÃ÷
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2023-04-05
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
¾Ë¸²
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.
°æ°í
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡± ¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â ·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ